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ABSTRACT
A role of endothelial cells in the survival of CLL cells during extravasation 
is presently unknown. Herein we show that CLL cells but not normal B cells can 
receive apoptotic signals through physical contact with TNF-α activated endothelium 
impairing survival in transendothelial migration (TEM) assays. In addition, the 
CLL cells of patients having lymphadenopathy (LApos) show a survival advantage 
during TEM that can be linked to increased expression of α4 and αL integrin chains. 
Within this context, ephrinA4 expressed on the surface of CLL cells sequestrates 
integrins and inactivates them resulting in reduced adhesion and inhibition of 
apoptotic/survival signals through them. In agreement, ephrinA4 silencing resulted 
in increased survival of CLL cells of LApos patients but not LA neg patients. Similarly 
was observed when a soluble ephrinA4 isoform was added to TEM assays strongly 
suggesting that accumulation of this isoform in the serum of LApos patients 
could contribute to CLL cells dissemination and survival in vivo. In supporting, 
CLL lymphadenopathies showed a preferential accumulation of apoptotic CLL cells 
around high endothelial venules lacking ephrinA4. Moreover, soluble ephrinA4 
isolated from sera of patients increased the number and viability of CLL cells 
recovered from the lymph nodes of adoptively transferred mice. Finally, we present 
evidence suggesting that soluble ephrinA4 mediated survival during TEM could 
enhance a transcellular TEM route of the CLL cells. Together these findings point 
to an important role of ephrinA4 in the nodal dissemination of CLL cells governing 
extravasation and survival.
INTRODUCTION
Compelling evidence supports that CLL cell survival 
within the tumor microenvironment is highly dependent 
on extrinsic signals provided by non-leukemic cell types 
[1, 2]. Endothelial cells can protect CLL cells from 
spontaneous apoptosis in vitro through soluble factors and/
or direct physical contacts [1–7]. Both findings suggest 
that endothelial cells could play a similar role during 
extravasation an issue that, to our knowledge, has not been 
previously addressed. It has been emphasized a major 
effect of transendothelial migration (TEM) in the survival 
of non-leukemia cell types including granulocytes [8], T 
lymphocytes [9] or CD34+CD14+ monocyte precursors 
[10]. In agreement, the extravasation through inflamed 
vascular vessels or the specialized high endothelial venules 
(HEV) in lymphoid tissues [11] could affect the survival 
outcome of CLL cells.
In CLL cells, the TEM capacity is strongly 
dependent on α4 (CD49d) expression which together with 
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αL integrin (CD11a) contributes to enhance it in patients 
having lymphadenopathy [12–14]. CD49d can also 
mediate contact dependent survival of CLL cells within 
tumor microenvironment [6, 15] associating with inferior 
prognosis groups including unmutated (UM) IgHV or 
CD38 expressing cases. Together these lines of evidence 
strongly suggest that integrin dependent extravasation 
may be further linked to a survival advantage that needs, 
however, a definitive demonstration.
Moreover, CLL cells show a reduced TEM 
compared to that of normal B cells as demonstrated under 
static or flow in vitro TEM conditions [12, 14, 16] and 
in an adoptively transferred mice in vivo model [12]. We 
showed that this can be in part linked to overexpression 
of ephrinA4, a GPI-membrane-linked ligand of the Eph 
receptor family of tyrosine kinases which is found as 
a membrane bound and a soluble isoforms in CLL and 
normal B cells [17, 18]. Reverse signaling through the 
cell surface expressed isoform inhibits integrin mediated 
adhesions of CLL cells to endothelium through binding 
to EphA2 receptor on the surface of endothelial cells [16, 
19] likely impairing extravasation. By contrast, the soluble 
isoform enhances TEM of CLL cells in vitro when bound 
by endothelial cells through EphA2. This process could 
be coupled to enhanced diapedesis through sequestration 
and internalization of ICAM-1 and VCAM-1 [16] rather 
than through increased vascular permeability of the altered 
endothelial junctions found after ephrinA1 treatment 
[20]. Moreover patients having lymphadenopathy 
show increased serum levels of ephrinA4 in addition 
to decreased expression of ephrinA4 on the surface 
of CLL cells [18]. Together these findings pointed to 
soluble isoform as a likely mechanism contributing to 
nodal dissemination of CLL cells which needed further 
confirmation in a more physiological in vivo setting 
[21–23]. Herein we present for the first time in vitro and 
in vivo evidence suggesting that the major role of two 
ephrin A4 isoforms in CLL could be related with a non-
previously described mechanism of survival linked to 
extravasation strongly dependent on integrin signaling.
RESULTS
CLL cells, but not normal B cells, can suffer 
apoptosis through physical contact with TNF-α 
activated endothelium resulting in impaired 
survival after transendothelial migration (TEM)
The possible impact of extravasation in the survival 
of CLL cells was analyzed in the widely accepted [24] 
transendothelial migration (TEM) assays. HUVEC 
monolayers grown onto the filters were preactivated 
for 4 hour with TNF-α and then extensively washed in 
fresh culture medium before addition of the CLL cells 
onto them. The percentage of apoptotic (Annexin-V pos 
7AAD neg) and viable cells (Annexin-V neg 7AAD neg) 
were measured by flow cytometry in the transmigrated 
(TM) and the non-transmigrated (non-TM) fractions after 
4 or 12 hours. Values were compared to basal levels in 
control suspension cultures done in the bottom chambers 
of separate wells having or not a TNFα pretreated 
HUVEC monolayer onto the filter. A clear increase in 
the spontaneous apoptosis in control suspension cultures 
was only evidenced after 12 hours (Supplementary 
Figure S2) resulting in decreased viability irrespectively 
of the presence of a TNF-HUVEC monolayer on top of 
the filter (Figure 1A-i) discarding any effect of soluble 
factors from endothelium. The viability of CLL cells in 
the TEM assays was even more decreased in the two TEM 
fractions and, especially, in the TM cells compared to 
basal levels in the control suspension cultures in bottom 
chambers (Figure 1A-i) indicating that direct contact 
with endothelium was involved in these effects. Normal 
B cells suffered no significant changes in viability or an 
increased one in some samples (Figure 1A-ii) suggesting 
a proapoptotic effect of endothelium specifically in the 
CLL cells. Importantly, CLL cells transmigrating through 
non-activated HUVEC showed no significant changes in 
viability compared to basal levels (Supplementary Figure 
S3) highlighting that only activated endothelium mediated 
the apoptotic signals. The low cellular density in bottom 
chambers could explain the decreased viability of TM cells 
compared to the non-TM ones. However, no significant 
improvement in viability of TM cells was found when cell 
numbers in the bottom chambers were increased through 
direct addition of CLL cells at the initiation of the assays 
(Supplementary Figure S4). To further confirm that CLL 
cells could receive apoptotic signals while crossing the 
TNF-HUVEC monolayer we examined TUNEL stained 
filters through confocal microscopy. This demonstrated the 
occurrence of numerous apoptotic CLL cells in both sides 
of the filters with TNF-HUVEC compared to untreated 
HUVEC assays (Figure 1A-iii). Although absolute 
numbers of total and apoptotic CLL cells predominated 
in the upper side of filters (Figure 1A-iii, cartoons) the 
frequency of apoptotic cells was significantly higher in 
the underside (Figure 1A-iii) in agreement with a higher 
frequency of apoptotic cells in the bottom than the upper 
chambers, as determined by flow cytometry (Figure 1A-i). 
Together these data supported that CLL cells receive 
apoptotic signals during TEM.
Since previous studies had reported prosurvival 
effects of endothelium in CLL cells cocultured several 
days [1–7], we analyzed the endothelium role in CLL 
viability cocultured onto TNF-α or unstimulated HUVEC 
monolayers at 12 hours or at longer time points 2 or 5 
days. In line with previous studies [1–7] we observed a 
prosurvival effect onto unstimulatedand to a lower extent 
TNF-HUVEC but not earlier than 2 days (Figure 1B-i). 
Indeed, these prosurvival effects with TNF-HUVEC 
were preceded by a drop in CLL viability at 12 hours 
(Figure 1B-i) in concert with our TEM assays. In 
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Figure 1: Physical contacts of CLL cells with TNF-αactivated endothelial cell monolayers during transendothelial 
migration (TEM) impair survival of leukemia cells. A. CLL cells from 10 patients (n. 1-10; Table 1) (i) or normal B cells isolated from 
the peripheral blood of 10 healthy donors (ii) were added onto TNFα pretreated confluent monolayer of HUVEC (TNF-HUVEC) in transwell 
plates (Transendothelial Migration (TEM) assays) or to the bottom compartment of separate transwells (Suspension cultures)(5×105 cells/well). 
Suspension cultures of CLL cells were carried out in bottom wells either with or without a TNF-HUVEC onto the upper filter. The percentage of 
apoptotic and viable cells in each experimental condition were determined after 12 hours by flow cytometry analysis of Annexin-V-PE/7AAD 
double staining. Each experimental condition was compared to basal levels in control suspension cultures without HUVEC (TEM assays: non-
TM, non-transmigrated; TM, transmigrated). (iii) Transwell filters of TEM assays with CLL cells performed with TNF-α activated (+TNF) or 
untreated HUVEC (No TNF) were fixed and fluorescently stained with TUNEL (red; apoptotic nuclei), anti-CD31 (green; HUVEC junctions) 
and Hoechst (blue; total nuclei). Laser confocal microscopy images were taken from the upper and underside of filters (magnification 20x; ≥ 3 
microscopy fields per filter; 1-2 filters per sample). Cartoons are from a representative TEM experiment with TNF-HUVEC. Total and TUNEL 
stained nuclei were counted (Image J; > 200 nuclei per sample and experimental condition) and the frequency of apoptotic cells in each side of 
the filters calculated (Right panel). Note that although the absolute number of nuclei was higher in the upper than the undersides the percentages 
of apoptotic CLL cells increased in the later one. Data are mean (±SD) from ten independent samples. B. i) CLL cells were cultured onto alive or 
paraformaldehyde fixed (fixed) TNF-α preactivated or untreated confluent HUVEC monolayers. The percentages of viable CLL cells (Annexin-
V-neg 7AAD neg) were determined at the indicated time points by flow cytometry and compared to control suspension cultures without HUVEC. 
ii) CLL cells were cultured for 12 hours in suspension or onto alive HUVEC with normal culture medium or conditioned medium from 5 days 
CLL-HUVEC cocultures. iii) CLL cells were harvested at the indicated time-points from cocultures onto untreated or TNF-activated HUVEC 
and left in culture alone up to 12 hours. Two-tailed Student’s t-test significance values: * P<0.05; ** P<0.01; *** P<0.001; n.s. non-significant.
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addition, paraformaldehyde fixed instead of alive 
HUVEC monolayers lacked any prosurvival effects in the 
cocultured CLL cells and, more importantly, emphasized 
the proapoptotic ones onto TNF-HUVEC even at 2 or 5 
days (Figure 1B-i) pointing to the release of prosurvival 
soluble factors in the alive conditions. Indeed, conditioned 
media from 5 days cocultures with alive HUVEC had 
prosurvival effects in the CLL cells cultured for 12 hours 
alone or under any coculture condition (Figure 1B-ii) 
definitively demonstrating that soluble prosurvival 
factors accumulate after prolonged coculture. We further 
concluded that 2 hours coculture of CLL cells with TNF-
HUVEC was sufficient to receive proapoptotic signals that 
irreversibly led to their apoptosis when harvested and left 
in culture alone until 12 hours (Figure 1B-iii).
Together these data conclusively demonstrated 
that CLL cells suffer apoptotic signaling through 
direct contacts with TNF-HUVEC and likely during 
extravasation which needed further investigation.
CLL cells of patients having lymphadenopathy 
(LApos) have a survival advantage during TEM 
mediated by α4 and αL integrin chains
Having stablished that TEM impairs survival of CLL 
cells, we examined its possible association with disease 
related parameters including lymphadenopathy (LA), 
IGHV gene mutational status or ZAP-70 or CD38 antigens 
expression. To this end, the sample size was increased 
by including 20 additional patients in TEM assays 
(Table 1). In all cases examined we confirmed a decline 
in the viability of both TEM fractions relative to basal 
levels and mainly in the TM cells (from 68% mean basal 
values to 48% mean values in the TM cells) (Figure 2A-i). 
Nevertheless, because the viability levels in TEM assays 
varied between samples we normalized them to the basal 
ones as a measure of survival outcome. This allowed us to 
find a significant association with the lymphadenopathy 
(LA) condition of patients and to a lower extent ZAP-70 
rather than IGVH mutational status or CD38 expression 
(Figure 2A-ii). Samples having lymphadenopathy (LApos) 
showed a better survival outcome than those lacking it 
(LAneg) (Figure 2A-ii) suggesting a possible association 
with the TEM capacity. In supporting this conclusion 
we found a strong correlation of survival outcome with 
the TEM rate of samples (Figure 2A-iii) that largely 
associated with LA condition rather than other parameters 
(Supplementary Figure S5A).
Because α4 integrin expression in LApos cases 
have been correlated with enhanced TEM capacity 
[12–14] and mediate survival signals from endothelium 
[6, 15], we investigated its possible association with TEM 
survival outcome. As determined by flow cytometry, the 
cell surface expression of α4 and αL integrins and their 
corresponding β chains were lower in CLL cells than 
in normal B cells although significantly increased in 
LApos respect to LAneg cases (Figure 2B-i) in concert 
with enhanced TEM rate (Supplementary Figure S5B-C). 
Interestingly, there was a strong correlation of α4, rather 
than αL expression, with the survival outcome of TM 
cells (Figure 2B-ii) further supporting a specific role of α4 
integrin in this outcome.
To further confirm this, we blocked α4 or αL 
interactions in separate TEM assays through preincubating 
the CLL cells of LApos and, for comparison, LAneg cases 
with recombinant forms of VCAM-1 (rhVCAM-1) or 
ICAM-1 (rhICAM-1) endothelial ligands, respectively. 
Five samples having different α4 or αL expressions within 
each LA clinical conditions were compared (Figure 2C). 
LApos cases showed a strong reduction in the TEM rate 
after blocking either of the two integrin interactions 
(Figure 2C-i) in contrast to LAneg samples (Figure 2C-i) 
confirming that both integrin chains play a critical role in 
TEM of LApos cases. Moreover, the viability of both, non-
TM and TM cells, was strongly improved in the LApos 
cases under blocking either of the two integrins compared 
to the untreated samples while only αL blocking did in 
the LAneg cases (Figure 2C-ii). The bound recombinant 
ligands had no significant effects in the viability of 
CLL cells in control suspension cultures (Figure 2C-ii) 
indicating that their effects in TEM assays can be linked 
to the inhibition of the corresponding integrin interactions 
with endothelium. The survival outcome of TM cells was 
greatly improved in the LApos cases compared to that in 
control untreated assays (Figure 2C-iii). However, it was 
impaired relative to the non-TM cells compared to the 
control cultures (Figure 2C-iii) suggesting that integrin 
interactions rescued the CLL cells during diapedesis from 
proapoptotic signals received at initial adhesions.
In conclusion, these data showed that the integrin 
adhesions responsible of the enhanced TEM of CLL cells 
are also critically involved in the survival outcome.
Integrin dependent survival outcomes are 
counteracted by ephrinA4 reverse signaling
Having stablished that integrins enhance the survival 
outcome of TM CLL cells in LApos patients, we analyzed 
its possible modulation through ephrinA4 reverse signaling 
as previously reported by us [16]. As determined by flow 
cytometry, ephrinA4 expression was significantly higher 
in LAneg than LApos samples (Figure 3A-i) while no 
significant differences were found according to ZAP-70, 
IGVH or CD38 parameters (Figure 3 A-i) confirming its 
association with the LA condition of patients previously 
found by us [16, 18]. Remarkably, ephrinA4 expression 
levels were low in most trisomy 12 (tris12) cases (4 out of 5) 
and, to a lower extent, del11q positive samples (3 out of 4) 
(Figure 3A-i) which could be in concert with the increased 
risk to suffer lymphadenopathy in these patients. EphrinA4 
expression and TEM survival followed an inverse correlation 
in both LA clinical groups (Figure 3A-ii) contrasting with 
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that observed for integrins (Figure 2B-ii). Accordingly, 
expression of ephrinA4 and CD49d followed an opposite 
pattern and, in the LApos cases, the appearance of a CD49d 
high population correlated with a low ephrinA4 expression 
(Figure 3B). Together these data further supported a direct 
and/or indirect role of ephrinA4 in the survival events during 
TEM modulating integrin adhesions.
To discriminate between these two possibilities 
we preincubated the CLL cells from the 30 patients with 
saturating amounts of recombinant extracellular domains 
Table 1: Clinical and molecular details of patients
N. G. Age(y) Rai LA IgHVa ZAP-
70b
CD38c del13q del17p del11q +12 ephrinA4d Integrin chaine
αL β2 α4 β1
1 F 74 low no M neg neg - - - + 15.90 11.95 32.06 25.00 21.93
2 M 69 low no M neg pos - - - - 30.90 7.37 22.91 9.53 45.00
3 F 91 int yes UM neg pos - - - - 20.20 13.32 67.84 63.80 55.24
4 M 59 int yes M neg pos - - - - 7.70 13.20 57.45 24.28 50.74
5 M 78 hi no M pos neg + - - - 17.80 17.46 30.44 26.00 15.36
6 M 73 hi yes M pos pos - + - - 10.70 7.84 23.85 89.00 55.00
7 F 69 hi yes M pos neg - - - - 6.30 7.60 14.45 52.00 45.00
8 F 69 low no UM neg neg + - - - 36.47 9.92 13.69 19.60 7.58
9 F 78 int yes M neg neg - - - - 10.25 8.73 29.23 63.56 35.00
10 F 73 int yes M neg pos + - - - 7.83 42.12 65.56 56.78 59.23
11 F 65 hi yes UM pos neg + + - - 6.44 5.89 13.56 54.00 33.62
12 M 76 int yes UM pos neg + - - - 10.99 10.54 19.81 45.00 53.71
13 F 71 int yes M pos neg - - - + 12.62 35.48 56.68 16.53 69.67
14 F 58 hi yes M neg neg - - - - 10.46 10.85 21.07 78.00 63.00
15 M 69 int yes UM pos pos + - - - 9.63 51.00 54.00 56.00 25.00
16 F 63 int yes M neg neg. + - - + 11.25 20.00 23.00 98.00 65.00
17 M 79 int no UM neg neg - - - + 56.25 32.00 25.00 12.00 27.00
18 F 62 int yes M neg n.d. - - - - 6.98 8.00 68.00 34.00 32.00
19 F 85 int yes M pos neg - - - + 4.69 6.00 66.00 65.25 45.00
20 F 77 int yes UM pos neg + - - - 26.53 24.00 52.00 65.00 56.00
21 F 88 low no M pos neg + + + - 14.35 15.00 36.00 15.00 65.00
22 F 72 low no UM pos neg + - + - 62.25 7.00 35.00 15.00 53.00
23 M 75 low no UM pos neg + - - - 70.00 18.00 15.00 18.00 21.00
24 F 83 hi yes UM neg neg - - - - 18.69 33.00 84.00 70.00 45.00
25 F 58 low no M pos pos - + - - 68.00 26.00 29.00 33.00 56.00
26 F 66 low no UM pos neg + - + - 25.25 35.00 33.00 35.00 25.00
27 M 73 low no M pos neg + - - - 36.25 12.00 38.00 39.00 21.00
28 M 73 int yes M pos neg - - - - 14.56 54.00 61.00 66.00 68.00
29 M 68 low no UM pos pos + - - - 11.25 9.00 15.00 52.00 23.00
30 M 85 int yes UM pos pos + - + - 11.25 36.00 12.00 63.00 33.00
Footnotes: a Sequences with a germline homology of ≥ 98% were considered as UM; b, c Determined by flow cytometry 
(Positivity cut off over isotype stained negative control stainings): ZAP-70, > 25% stained cells; CD38, > 35% stained cells; 
d, e Mean Fluorescence Intensity (MFI) determined by flow cytometry.
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Figure 2: CLL cells of patients having lymphadenopathy (LApos) show a survival advantage during TEM mediated by αL 
and α4 integrins. A. TEM assays through TNF-HUVEC were done with 30 patients and viability determined by flow cytometry analysis after 
12 hours. i) Absolute values of viable cells. ii-iii) Viability of TM cells relative to basal levels in control suspension cultures without HUVEC (TM 
survival outcome) according to the indicated disease parameters (ii). iii) Linear correlation analysis between TM survival outcome and TEM rate. 
Absolute number of TM CLL cells, recovered from the bottom chambers, was measured by flow cytometry and expressed as percentage of total 
input cells (TEM rate). R, Spearman’s correlation coefficient. B. Cell surface expression of the indicated integrin chains was measured in normal 
B cells and CLL cells by flow cytometry after staining with antigen specific antibodies. i) Whisper-box plots compare integrin expression levels 
(mean fluorescence intensity, MFI) between CLL cells and normal B cells, and between CLL cells of patients having or not lymphadenopathy 
(LApos and LAneg, respectively). ii) Linear correlation analysis between survival outcome of TM cells and expression of αL (upper plot) or α4 
(lower plot) integrins. R, Spearman’s correlation coefficient. C. CLL cells from 10 patients, having (LApos) or not (LAneg) lymphadenopathy, 
were preincubated or not (untreated) with recombinant soluble forms of human VCAM-1 (+rhVCAM-1) or ICAM-1 (+rhICAM-1) and left 
transmigrating through TNF-HUVEC monolayers (TEM assays) or cultured in suspension (suspension cultures) for 12 hours. Integrin expression 
levels (MFI) of the used samples are shown. i) TEM rate of samples were compared to that in control (untreated) TEM assays in LApos and 
LAneg cases. ii) Absolute levels of viable CLL cells in suspension cultures or in TEM assays (non-TM and TM cells) after rhVCAM-1 or 
rhICAM-1 preincubation. Treatments are compared to control (untreated) assays. iii) Viability of TM cells as percentage of a reference population: 
basal levels (suspension cultures) or non-TM cells. Paired two-tailed Student’s T test significance values: * P<0.05; ** P<0.01; *** P<0.001.
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Figure 3: EphrinA4 reverse signaling suppresses integrin mediated survival signals through inhibiting activation state. 
A. Expression of ephrinA4 was measured on the surface of CLL cells from 30 samples by flow cytometry analysis (MFI, mean fluorescence 
intensity) and (i) compared between samples according to disease parameters and cytogenetic characteristics or (ii) correlated with survival 
outcome of TM cells in LApos (left) and LAneg (right) cases. R: Spearman’s correlation coefficient. B. Expression of ephrinA4 and CD49d 
(α4) on the surface of CLL cells was determined by flow cytometry (upper panels). Correlation analysis between ephrinA4 and α4 expression 
(mean fluorescence intensity, MFI) of samples. C. CLL cells from 30 patients (i, LApos; ii, LAneg) were preincubated (+EphA2Fc) or 
not (No treatment) with saturating amounts of soluble recombinant human EphA2 extracellular domains (EphA2Fc) and cultured for 12 
hours in suspension in untreated plates (control) or plates containing the indicated molecules pre-immobilized to wells. BSA was used as 
a non-specific immobilized protein. Viability of CLL cells onto each protein is shown as percentage of basal levels in control suspension 
cultures without immobilized proteins. Statistical significances are shown for comparison between untreated cultures to control cultures or for 
EphA2Fc treatments to untreated conditions. Whisper-box plots: mean (+) and median (-) values. D. CLL cells from LApos samples (n=3) 
were preincubated in suspension with poly-His tagged EphA2Fc or hFc as control. Cell suspensions were then incubated with biotin anti-His 
followed by AlexaFluor488 streptavidin and adhered to slides for 15 min (37°C). After paraformaldehyde fixation (4% PF in PBS) slides 
were incubated with AlexaFluor647 conjugated monoclonal Ab for the indicated integrin chains and analyzed through confocal microscopy 
(Supplementary Figure S6). At least 3 fields per experiment were evaluated for colocalization analysis (Colocalization Tool, Image J). ≥ 200 
cells per sample were analyzed. E. CLL cell suspensions (105 /assay) were incubated for 30 min with EphA2Fc or Fc only in RPMI/2% FCS 
(Normal medium) or containing 1mM MnCl2 (Mn2+). Next, CLL cells were incubated with a PE coupled HUTS21 mAb in cold PBS (i) or PE 
coupled anti-Fc preclustered VCAM-1-Fc in normal medium (ii) followed by flow cytometry analysis. A representative LApos CLL sample is 
shown (n>3 samples). Paired two-tailed Student’s T test significance values: * P<0.05; ** P<0.01; *** P<0.001.
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of human EphA2 (EphA2Fc) which results in ephrinA4 
reverse signaling modulating integrin affinity [16]. The 
viability of CLL cells was analyzed, as in the preceding 
TEM assays, at 12 hours of culture in suspension alone 
or onto plate immobilized rhICAM-1 or rhVCAM-1 or 
other integrin ligands of the extracellular matrix (ECM) 
including fibronectin (FN), collagen type-1 (CL-1), laminin 
(LM) or vitronectin (VN). EphA2Fc did not significantly 
affect the viability of CLL cells cultured onto immobilized 
BSA relative to control assays (Figure 3C-i-ii) discarding 
a direct role of ephrinA4 reverse signaling in CLL cell 
viability. However, it largely counteracted most of the 
effects onto integrin ligands (Figure 3C-i-ii), including the 
prosurvival ones observed in LApos cases onto either of the 
two endothelial ligands. ECM molecules mainly induced a 
decrease in the viability of CLL cells of all samples (Figure 
3C-i, ii) excluding FN which had prosurvival effects in 
LApos cases (Figure 3C-i-ii) confirming the critical role of 
α4 in this clinical group. These data agreed with prosurvival 
signals mediated by αL and, mainly, α4 integrins in LApos 
cases during diapedesis, as concluded from blocking them 
in the preceding TEM assays, and further highlighted a role 
of ephrinA4 in regulating them. In line with our previous 
findings [16], EphA2Fc induced a significant increase in 
the number of non-adhered CLL cells recovered from the 
adhesion assays (not shown) which occurred in the absence 
of a significant decrease in integrin expression (not shown). 
Confocal fluorescence microscopy demonstrated a lack of 
intracellular staining for integrins but rather showed their 
sequestration on the surface of the EphA2Fc treated CLL 
cells (Supplementary Figure S6) (Figure 3D). These results 
suggested that physical interactions on the cell surface 
rather internalization could modulate the integrin binding 
capacities. Indeed, flow cytometry analysis of HUTS-21 
Abs staining, which recognizes high affinity conformations 
of VLA4 integrins, demonstrated that EphA2Fc treatment 
strongly inactivated VLA4 in the CLL cells even when 
artificially activated through addition of Mn2++ to medium 
(Figure 3E-i). Accordingly, binding of soluble VCAM-1-Fc 
by CLL cells was dramatically reduced in the presence of 
EphA2Fc (Figure 3E-ii). In conclusion, these data supported 
that ephrinA4 signaling inhibits integrin affinities for their 
ligands and, hence, apoptotic/survival signals.
Absence of ephrinA4 reverse signaling 
dramatically improves the survival of TM CLL 
cells from LApos cases
To demonstrate a role of ephrinA4 reverse signaling 
in TEM assays, CLL cells were preincubated with saturating 
amounts of the EphA2Fc recombinant molecules. Under 
these conditions, bidirectional signaling between CLL and 
endothelial cells through the receptor-ligand pair is inhibited 
while ephrinA4 reverse signaling into the CLL cells still 
can take place [16]. In these experiments, six samples of 
each LA condition were chosen that differed in ephrinA4 
expression levels within each group (Figure 4C; Table 1). 
In line with our previous findings [16], rhEphA2 did not 
significantly changed integrin expression of CLL cells 
(Figure 4A) but led to a marked drop in the TEM rate of 
all samples (Figure 4B) in concert with the inhibition of 
integrin adhesions. Indeed, as in the integrin blocking TEM 
assays, it significantly increased both the viability of non-
TM and TM cells in all samples (Figure 4C-i) and, more 
importantly, the survival outcome of TM cells relative to 
basal levels in suspension cultures but not relative to the 
non-TM ones of LApos cases (Figure 4C-ii). Altogether, 
these data supported that ephrinA4 reverse signaling during 
diapedesis likely inhibits integrin prosurvival signals into 
the CLL cells of LApos cases.
Next, we blocked ephrinA4 signaling in TEM 
assays through siRNA mediated silencing of EphA2 in 
the endothelial cells. However, absence of this receptor 
in the endothelial cells rendered them unable to form a 
tightly packed monolayer (Figure 4D) thus limiting further 
TEM assays. Next, we challenged ephrinA4 silencing in 
the CLL cells from the 6 LApos and LAneg cases used 
in the preceding EphA2Fc TEM. Forty-eight hours after 
nucleofection, we found a strong reduction of ephrinA4 
expression on the cell surface (Figure 5A) without 
significantly compromising their viability as compared 
to untreated or control nucleofected samples. EphrinA4 
knock-down had not significant effects on the expression 
of integrins but markedly reduced the TEM rate of 
samples as compared to siRNA neg or untreated CLL 
cells (Figure 5B-i) and the number of CLL cells retained 
onto the HUVEC monolayer increased as determined 
by fluorescent microscopy analysis of transwell filters 
(Figure 5Bii-iii). Collectively, these findings confirmed 
that ephrinA4 decreases adhesion [16, 18]. In terms of 
viability, ephrinA4 knock-down led to a marked decrease 
in the viability of non-TM cells of both LA clinical groups 
compared to siRNA neg nucleofected or untreated cells 
(Figure 5C-i) which was compatible with the increased 
adhesion and, hence, occurrence of proapoptotic signals 
at initial steps of TEM. By contrast, the viability of TM 
cells was dramatically improved in the LApos but not the 
LAneg cases compared to that in untreated samples and, 
more importantly, to their corresponding non-TM cells 
(Figure 5C-i) a finding also confirmed in terms of survival 
outcome (Figure 5C-ii). Together with the preceding 
integrin blocking or EphA2Fc TEM assays, these results 
supported that switching-off ephrinA4 reverse signaling 
during diapedesis represented a survival advantage for the 
CLL cells of LApos cases.
Soluble ephrinA4 binding to endothelium 
strongly potentiates survival advantage of CLL 
LApos cases
As previously demonstrated by us [18], herein 
we confirmed higher levels of soluble ephrinA4 in the 
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Figure 4: EphrinA4 reverse signaling inhibits survival signaling during diapedesis. CLL cells from the indicated patients 
having (LApos) or not (LAneg) lymphadenopathy were preincubated with EphA2Fc or hFc or left untreated and allowed transmigrating 
through TNF-HUVEC monolayers (TEM assays) or cultured in suspension (suspension cultures) for 12 hours. A. Representative flow 
cytometry histograms of α4 or αL integrin expression in CLL cells before and after incubation with EphA2Fc. B. TEM rate of samples, 
as determined by flow cytometry, were compared between hFc or EphA2Fc treatments to untreated cultures in LApos and LAneg cases. 
C. Effects of EphA2Fc in viability of CLL cells. i) Absolute levels of viable CLL cells in suspension cultures or in TEM assays (non-TM 
and TM cells) after rhEphA2Fc or hFc treatment compared to control, untreated CLL cells. ii) Relative viability of TM cells as percentage 
of basal levels in suspension cultures or of the corresponding non-TM cells. D. HUVEC were nucleofected with EphA2 specific or negative 
control siRNA. VE-Cadherin (green) stained HUVEC cultures demonstrated that EphA2 silencing inhibited the formation of a proper 
confluent monolayer. Paired two-tailed Student’s T test significance values: * P<0.05; ** P<0.01; *** P<0.001.
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serum from patients having lymphadenopathy than in 
those lacking it (Figure 6A) whereas a clear association 
with other parameters was not found (Figure 6A). 
Mechanistically, soluble ephrinA4 enhances extravasation 
of CLL cells after binding to EphA2 receptor on the 
surface of endothelial cells [16] through inhibiting cell 
surface expressed ephrinA4 mediated reverse signaling, 
thus allowing integrin mediated adhesions. Furthermore, 
EphA2 mediated sequestration and internalization of 
VCAM-1 and ICAM-1 endothelial ligands could be 
involved in this process [18]. To analyze whether this 
mechanism could contribute to improve the survival of 
CLL cells in TEM assays, we preincubated the TNF-
HUVEC monolayer with saturating amounts of soluble 
recombinant human ephrinA4 (ephrinA4Fc) as previously 
described [18]. This resulted in an increased TEM rate of 
LApos but not the LAneg cases (Figure 6B-i) confirming 
our previous findings [16]. Moreover, the viability of non-
TM and TM cells of LApos samples was dramatically 
improved (Figure 6B-ii) along with an enhancement in 
Figure 5: Absence of ephrinA4 reverse signaling during TEM increases survival outcome of TM cells in LApos samples. 
CLL cells of the 12 patients used in EphA2Fc assays having (LApos) or not (LAneg) lymphadenopathy (Figure 4), were nucleofected 
with ephrinA4 specific or negative control siRNA duplexes or left untreated. A. EphrinA4 silencing was determined by flow cytometry 
48 hours after nucleofection. B. Untreated or nucleofected cells (siRNA neg or ephrinA4) were left transmigrating for 12 hours through 
TNF-HUVEC. i) TEM rate of samples measured by flow cytometry. ii) Transwell filters from TEM assays were stained with anti CD31 
mAb (green, HUVEC junctions) and Hoechst (blue, nuclei) and examined by confocal microscopy (40x oil immersion; Leica TCS-SP2). 
CD31 junctions were not altered in the HUVEC monolayer of ephrinA4 knock-down samples. iii) Absolute counts of CLL cells adhered to 
TNF-HUVEC were measured by image analysis (ImageJ; > 200 nuclei counted per filter). C. Analysis of CLL cells viability in TEM assays 
after ephrinA4 knock-down. i) Absolute levels of viable CLL cells in suspension cultures or in TEM assays (non-TM and TM cells) were 
compared between ephrinA4-specific or neg control siRNA nucleofected to control untreated CLL cells. ii) Relative viability of TM cells 
as percentage of basal levels in suspension cultures or of non-TM cells. Paired two-tailed Student’s T test significance values: * P<0.05; 
** P<0.01; *** P<0.001.
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Figure 6: Treatment of TNF-HUVEC with soluble recombinant human ephrinA4 strongly potentiates survival of CLL 
cells and a possible transcellular TEM pathway. A. Soluble ephrinA4 levels in the serum of CLL patients were determined by 
indirect ELISA (ng/mL) and possible associations with clinical parameters examined. B. CLL cells from 12 patients having (LApos) or 
not (LAneg) lymphadenopathy, used in the EphA2Fc or siRNA assays (Figures 3 and 4), were left transmigrating 12 hours through TNF-α 
preactivated HUVEC monolayers preincubated (30 min) with saturating amounts of recombinant human ephrinA4 (HUVEC+ephrinA4Fc), 
purified human Fc (HUVEC + hFc) or untreated before addition of CLL cells. i) Absolute number of transmigrated cells (TM) was counted 
by flow cytometry and expressed as percentage of total input cells (TEM rate). ii) Absolute levels of viable CLL cells in suspension cultures 
or in TEM assays (non-TM and TM cells) in the ephrinA4Fc or hFc treated TEM assays were compared to untreated conditions. iii) Relative 
viability of TM cells normalized to basal levels (suspension cultures) or to the corresponding non-TM cells in the ephrinA4Fc or hFc 
treatments compared to untreated TEM assays. C. i) Transwell filters were stained with anti VE-Cadherin (green, HUVEC junctions) and 
Hoechst (blue, nuclei) and examined by confocal microscopy. Adhered CLL cells were located at VE-Cadherin interendothelial junctions 
or separated from them. ii-iii) Caveolin-1 and ICAM-1 immunofluorescence staining of TEM assays done in chamber slides 2 hours after 
coculture with LApos CLL cells. ii) CLL cells inside of HUVEC were surrounded by caveolin-1 endothelial caveola (asterisks, > 1μm from 
VE-Cadherin junction) and ICAM-1. Insets show Z- views of caveolin and ICAM-1 staining for a a transcellular (TC) and a paracellular 
(PC) TEM CLL nuclei. iii) Measurement of CLL cells located within caveolin-1, at VE-Cadherin junctions or unclassified in ephrinA4Fc 
treated compared to untreated TNF-HUVEC after 2 hours coculture (at least 200 nuclei were counted per condition). Paired two-tailed 
Student’s T test significance values: * P<0.05; ** P<0.01; *** P<0.001.
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the survival outcome of TM cells compared to untreated 
control TEM assays (Figure 6B-iii), confirming a 
prosurvival role of soluble ephrinA4 during TEM of 
LApos CLL cells.
Next, immunofluorescence microscopy analysis of 
the transwell filters showed that VE-Cadherin+ junctions 
between HUVECs were unaltered in the ephrinA4Fc 
treatments (Figure 6C-i) discarding that CLL cells 
traversed through holes as a possible explanation to the 
increased survival. Moreover, CLL cells located at VE-
Cadherin junctions (Figure 6C-i), suggesting a paracellular 
(PC) TEM route, or at > 1μm from them possibly 
following a transcellular (TC) TEM routes, as previously 
demonstrated [25]. To confirm a TC TEM pathway, we 
examined by confocal microscopy a possible association 
between intracellular caveolin-1 staining, which has been 
related with this TEM route in lymphocytes [26, 27], and 
the CLL cells actually inside of endothelial cells located > 
1μm of interendothelial junctions. Many CLL cells inside 
of HUVEC were distinctly located within caveolin-1+ 
endothelial vacuoles and surrounded by ICAM-1 staining 
(Figure 6C-ii) suggesting a TC route of TEM. Image based 
counting of CLL cells at VE-Cadherin junctions or > 1μm 
within caveolin-1 in TEM assays revealed an increased 
frequency of the later under ephrinA4Fc treatments 
(Figure 6C-iii) in concert with an enhanced TC pathway 
through the endothelial cell body. These data confirmed 
that soluble ephrinA4Fc does not induce a TEM of CLL 
cells through disassembling interendothelial junctions but 
rather through endothelial cells themselves likely through 
a TC route of TEM.
EphrinA4 can be detected in the HEV of CLL 
lymphadenopathies and enhances viability 
of CLL cells infiltrating the lymph node of 
adoptively transferred mice
A possible correlation between apoptosis and 
in vivo extravasation was indirectly investigated by 
immunofluorescence microscopy analysis of CLL 
lymphadenopathies. Apoptotic cells were detected 
in tissue sections through TUNEL staining and their 
location relative to HEV through PNAd staining. At 
low magnification, we confirmed an accumulation of 
apoptotic cells within 200 μm areas under the capsule 
in the three LA studied (Figure 7A-i). Because normal 
lymph node architecture is profoundly effaced in 
CLL lymphadenopathies we referred to these areas 
concentrating apoptotic cells near the capsule as outer 
rather than cortical regions, and as inner regions to the 
deeper ones inside of the LA parenchyma. Interestingly, 
apoptotic cells were closer to HEV in outer than 
inner regions (Figure 7A-i) indirectly suggesting an 
association with extravasation. After extravasation normal 
lymphocytes are retained for hours within an area of < 
20 μm around the HEV of cortical lymph node regions 
before infiltrating the LN parenchyma [28], a feature that 
correlated with an accumulation of apoptotic cells around 
them. Indeed, we found that the number of apoptotic nuclei 
within ≤ 20 μm around the HEV was markedly higher in 
the outer than the inner LA areas (Figure 7A-ii) suggesting 
that they could represent recently extravasated CLL cells. 
Its possible association with ephrinA4 staining was further 
examined. EphrinA4 staining was found not only in the 
infiltrated CLL cells but also within the endothelial cells 
of HEV bound to EphA2 (Figure 7B-i). Quantification of 
ephrinA4 staining bound to EphA2 in HEV in outer and 
inner regions (Figure 7B-ii) revealed a significant higher 
frequency in the former (Figure 7B-iii) thus following 
a completely opposed distribution to that observed for 
apoptotic cells. Altogether these data supported a possible 
in vivo prosurvival role of soluble ephrinA4 related to the 
extravasation of CLL cells into lymphadenopathies.
To assess this in a more physiological condition, 
CFSE stained human CLL cells of LApos and LAneg 
patients were adoptively transferred to Balb/c mice 
receiving different amounts of a soluble ephrinA4 
purified from the sera of CLL patients. The percentage 
and viability of CLL cells was analyzed 24 hours later 
by flow cytometry (Supplementary Figure S1) in cell 
suspensions of the popliteal lymph node where the number 
of endogenous mouse lymphocytes is greatly lower than 
in other lymph nodes. EphrinA4 led to an increase in the 
proportion (Figure 7C, Bars) and viability (Figure 7C, 
lines) of the human CLL cells recovered from the lymph 
nodes of mice inoculated with LApos samples in a 
concentration-dependent manner.
DISCUSSION
Herein we provide evidence, for the first time, that 
CLL cells establish physical contacts with endothelia that 
can result in decreased survival during extravasation. In 
patients having lymphadenopathy, CLL cells are able of 
collecting prosurvival signals through αLβ2 and α4β1 
integrins linked to ICAM-1 and VCAM-1 mediated 
diapedesis. In these processes, the soluble form of 
ephrinA4, that accumulates in the sera of patients having 
lymphadenopathy [18], plays an instrumental role. In 
these patients, ephrinA4 binding to EphA2 receptor 
on the luminal side of endothelial cells facilitates 
the adherence and migration of CLL cells through 
the endothelial vessels of lymphoid tissues, coupling 
enhanced TEM to prosurvival signals. Thus, the present 
findings expand our previous studies on the role of 
ephrinA4 isoforms in CLL cell adhesion and TEM [16, 
18] by further connecting them to CLL cell survival and 
lymphadenopathy.
Our present results shed new light on the role 
of endothelial cells in CLL. In accordance with 
previous studies [3, 4, 6, 29–31] we demonstrate that 
endothelial cells can provide prosurvival signals to 
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Figure 7: Soluble human ephrinA4 in HEV of lymphadenopathies inversely correlates with apoptotic cells near HEV 
dramatically enhancing the number and viability of human CLL cells recovered from lymph node of adoptively 
transferred mice. A-B. Seven μm thick sections from frozen CLL lymphadenopathies (LA n.1, 2 and 3 corresponding to CLL patients 
n. 3, 18 and 28, respectively) were fixed in acetone and sequentially incubated with A) TUNEL (white) and antibodies against PNAd (red) 
or B) antibodies against PNAd (magenta), ephrinA4 (green), EphA2 (red). In all cases nuclei were counterstained with Hoechst (blue). 
Fluorescent images were taken in a laser confocal microscope (TCS SP-2 AOBS, Leica). A) Representative low magnification images (20x) 
of areas near the capsule (“Cortical” region, left panel) or deeper (>200um far from capsule, “Inner” regions; right panel). ii) Frequency 
of apoptotic nuclei around (≤ 20 μm) or separated from HEV in cortical and inner LA regions (*p<0.05; **p<0.01; ***p<0.001). B) i) 
HEV (PNAd+, magenta; dotted line) showed strong ephrinA4 staining co-localizing with EphA2. (63x). ii) Regions of interest (ROI) were 
traced around HEV according to EphA2 staining (left). Intensity of ephrinA4 staining within ROIs was measured (pseudocolor scale inset). 
iii) HEVs containing ≥ 10% pixels above 200 gray-scales were considered as positive. Whisper-box plots of > 20 measured fields from 
each LA section. Unpaired two-tailed Student’s t-test significance values were *p<0.01; **p<0.005; ***p<0.001. C. Human CLL cells 
were stained with CFSE fluorescent tracer and adoptively transferred into germ-free young Balb/c mice (2×107 per mice) by intravenous 
injection through the tail vein along with increasing concentrations of human soluble ephrinA4 purified from the sera of patients. Mice 
were sacrificed 24 hours later and cell suspensions from popliteal lymph nodes stained with an anti-mouse CD45 antibody, AnnexinV-PE 
and 7AAD for flow cytometry analysis. Human CLL cells were gated according to CFSE positivity and negativity for anti-mouse CD45 
(Suppl. Figure S1). Data (mean±SD) were compared to mice receiving human CLL cells in PBS without ephrinA4. Five animals were 
used per sample and experimental condition. Paired two-tailed Student’s T test significance values were *p<0.05; **p<0.01; ***p<0.001.
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the leukemia cells within infiltrated tissues which 
are largely mediated by the release of prosurvival 
soluble factors. This is dependent on physical contacts 
between both cell types likely favored by prolonged 
coexistence within the infiltrated tissues. In supporting 
this hypothesis we demonstrated a lack of prosurvival 
effects in prolonged cocultures when using PF fixed 
rather than alive HUVEC. Besides, conditioned medium 
from long term cocultures protected the CLL cells from 
spontaneous and TNF-HUVEC mediated apoptosis 
in overnight (12 hours) cultures. By contrast, the 
timeframe of extravasation process is not presumably 
long enough [27] to promote the release of soluble 
factors by endothelial cells while proapoptotic signals 
through physical contacts could predominate. This is 
supported by the increase of apoptotic CLL cells in 
the non-TM cells and can likely take place as early 
as 2 hours after contact as further demonstrated in 
cocultures. It would be interesting to confirm our 
results under flow conditions in a model recently used 
by other authors [13, 32] or through adapting flow 
conditions to transwells [33]. During diapedesis the 
CLL cells can be rescued from propapoptotic signals 
received at initiation of TEM in LApos cases. However, 
we cannot exclude that the migrated CLL cells could 
receive other survival signals once inside the lymph 
node parenchyma although our studies in LN sections 
show numerous apoptotic cells near to HEV. These data 
suggest that many recently migrated cells die without 
infiltrating the tissue and especially when migrating 
through the HEV lacking ephrinA4 that predominate in 
outer LA regions.
Our results also confirm a critical role of 
integrins in the pathobiology of CLL [13, 34–36] 
further emphasizing that they represent a link 
between extravasation and survival of leukemia cells. 
Increased levels of CD49d (α4) expression can be 
associated with inferior prognosis in IgHV-UM and 
CD38 expressing cases [37] and the occurrence of 
trisomy 12 likely associating with the appearance of 
lymphadenopathies [12-14, 22]. Its expression in CLL 
cells of LApos patients has been related with enhanced 
αLβ2 adhesion to ICAM-1 during transendothelial 
migration [34]. Indeed, CLL cells from patients lacking 
lymphadenopathy show a defective αLβ2 dependent 
motility and TEM which is in part corrected through 
expression of α4β1 in those suffering this organomegaly 
[34, 38]. This likely explains the lack of LAneg samples 
to receive prosurvival signal in TEM or when cultured 
onto ICAM-1 or VCAM-1 and further emphasizes the 
survival advantage of LApos cells. In agreement with 
previous studies highlighting a critical role of α4 in 
the endothelial mediated survival of CLL cells [6, 15, 
38, 39]] we further demonstrate that this is especially 
relevant in lymphadenopathy cases. By contrast, the 
finding of proapoptotic signaling mediated by these 
and/or other integrins in the CLL cells when cultured 
onto ECM ligands or that highlighted in TEM assays 
were completely unexpected. Integrins dual effects 
on cell survival, interchanging apoptosis or survival 
outcomes, have been found in other cell types including 
hematopoietic tumor cells [40–43]. This can be related 
with potentiated and sustained adhesion [40] or through 
unligated integrins [41] or their activation state prior 
to ligation recruiting caspases [41] and/or ERK rather 
than Akt kinase [42]. Together these mechanisms and/
or other unknown ones may contribute to the presently 
observed apoptotic outcome when adhering to inflamed 
endothelium through ligands different from ICAM-1 or 
VCAM-1.
In keeping with such an integrin dependent 
survival of CLL cells, cell surface expressed ephrinA4 
arises as a critical mediator counteracting apoptosis at 
initial adhesion steps and nonetheless the prosurvival 
ones in LApos CLL cells during diapedesis. Repulsive 
signals mediated by the surface expressed isoform, as 
previously shown by us [16], along with blood flow 
could likely contribute to detach the CLL cells from 
vascular vessels preventing adhesion related apoptotic 
signals. In LApos patients, by contrast, down regulation 
of membrane expressed ephrinA4 is needed to allow 
the firm adhesion to endothelium through α4 and αL 
integrins [16, 18]. Moreover, we show that ephrinA4 
is able of inhibiting high affinity conformational 
states of integrins through cell surface dependent 
physical sequestration rather than cell internalization. 
In supporting this mechanism, we also show enhanced 
adhesion to endothelium of ephrinA4 silenced CLL 
cells. The knock-down assays further demonstrate that 
absence of reverse signaling, but not of ephrinA4 itself, 
is necessary for LApos samples to go on with diapedesis 
but not for recruiting survival signals via integrins. 
The inverse association between ephrinA4 and CD49d 
molecules further highlights the possible existence of 
common mechanisms regulating their expression on 
the CLL cells to assure extravasation. Remarkably, 
in spite of the low number of tris12 and del11q cases 
included in the present study, most of them showed 
low ephrinA4 levels on the surface of CLL cells, a 
finding that could be linked to the increased tendency 
to develop lymphadenopathies in these patients.
Accordingly, it is on this basis that binding of the 
soluble ephrinA4 to endothelial EphA2 arises as a critical 
mechanism to promote TEM [21–23] coupled to survival 
in LApos cases. The finding of apoptotic CLL cells near 
HEV lacking ephrinA4 within the lymphadenopathies 
indirectly supported also the possible occurrence of this 
process in vivo. This was further confirmed in chimeric 
mice assays that, although not physiological at all, 
represent a good experimental protocol to study in vivo 
lymph node or bone marrow seeding capacity of human 
CLL cells [12, 44]. Besides we show that soluble ephrinA4 
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could promote a transcellular TEM route of CLL cells, as 
concluded from the VE-cadherin and caveolin-1 stainings 
of TEM assays, rather than through inducing holes in 
the HUVEC monolayer as observed in other endothelial 
studies of permeability using ephrinA1 rather than 
ephrinA4 [20]. Caveolin-1 mediated TC TEM is coupled 
to ICAM-1 and VCAM-1 transcytosis [26] similarly 
to what we have observed in the case of ephrinA4 
mediated internalization of EphA2 [16]. Moreover, 
EphA2 can physically interact with caveolin-1 as indeed 
demonstrated at a biochemical level [45]. Together these 
data may shed new light on the long lasting question 
about the significance of a TC versus a PC route of TEM 
[26, 27, 46].
Within this context, ephrinA4 could play an 
instrumental role in ensuring survival of the CLL 
cells linked to extravasation and lymphadenopathy, as 
summarized in Figure 8. In conclusion, our results provide 
new data on the survival mechanisms developed by CLL 
cells in vivo, demonstrating that extravasation could 
represent a disadvantageous event to be exploited for 
preventing nodal dissemination.
Figure 8: Summary of extravasation decisions and survival outcome of CLL cells according to lymphadenopathy 
condition determined by integrin and ephrinA4 mechanisms. In patients without lymphadenopathy (LAneg, left), CLL cells have 
low levels of α4 integrin expression impairing their extravasation but not adhesion to endothelium likely through αLβ2. In these conditions, 
a low frequency of CLL cells extravasate between adjacent endothelial cells (paracellular TEM route) without receiving prosurvival signals 
and finally die (2). Most CLL cells, however, will detach from endothelium as a result of their high ephrinA4 expression on the cell surface 
allowing them to continue flowing within blood (1). The levels of soluble ephrinA4 in the sera of LAneg patients are not high enough to 
counteract the binding of the cell surface expressed one to endothelial EphA2 and detachment. In patients with lymphadenopathy (right) 
(LApos) expression of α4 integrin is high enough to allow extravasation. In these patients, CLL cell adhesion to endothelium is facilitated 
by low expression of ephrinA4 on their surface and the high levels of soluble isoform in sera which binds to endothelial EphA2. As a 
result, adhesion to endothelium will take place facilitating apoptotic signals which, nonetheless, are counteracted in the CLL cells that 
successfully bind to ICAM-1 and VCAM-1 induced upon EphA2 aggregation. A mechanism coupling EphA2 to caveolin-1 could promote 




Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and national and international guidelines and has 
been approved by the authors’ institutional review board.
Patients
Patients gave written informed consent before 
inclusion in this study. Research has been approved by 
the Ethics and Research Committees of Universidad 
Complutense de Madrid and H. Morales Meseguer of 
Murcia according to the principles embodied in the 
Declaration of Helsinki. The sample size was calculated 
prospectively for each one of the disease parameters to 
be studied (Power =0.8; α< 0.05; SPSS Sample Power 
3, IBM). Under these criteria a total of 30 subjects were 
included (Table 1). FISH and IgHV gene mutational status 
analysis were performed according to previously published 
methods (Supplementary Material and Methods).
Blood samples were centrifuged onto density-
gradient (Histopaque 1.077, Sigma-Aldrich) incubated with 
lineage specific antibodies (Abs) in PBS (mouse anti-CD3, 
-CD2, -CD56, -CD14 and -CD13 antigens; BD Biosciences, 
Europe, Spain) followed by MACS-conjugated anti-mouse 
secondary Abs (Miltenyi Biotech, Spain) before depletion 
in an AutoMACS separator (Miltenyi Biotech, Spain). CLL 
or B cells purities were ≥98%.
Fresh small fragments of lymphadenopathies were 
available from three patients (CLL patients n. 3, 18 and 28; 
Table 1) that were embedded in cryoprotective medium 
(TissueTeck, Leica) and snap-frozen in liquid N2.
Transendothelial migration (TEM) assays
TEM assays were performed as previously 
described [16]. Briefly confluent monolayers of HUVECs 
(PromoCell, Spain) were grown onto the filters of 
transwell plates (96xwell transwell plates, 5 μm pore 
size, Corning) and stimulated or not with TNF-α (10 
ng/mL; PeProtech, Europe) for 4 hours. HUVEC were 
left by 6 hours in fresh medium without cytokine before 
addition of CLL or B cells onto them, for TEM assays, or 
in the bottom chambers for control suspension cultures 
(5×105/well). At the indicated time-points, cells were 
harvested in PBS from the bottom and upper chambers 
(transmigrated (TM) or non-transmigrated (non-TM) 
cells in TEM assays, respectively). Where indicated, 
cellular density was increased in the bottom chambers 
through direct addition of CFSE fluorescently prestained 
CLL cells (5×105/well) (5-(and-6)-Carboxyfluorescein 
Diacetate, Succinimidyl Ester of fluorescein; 10 μM; 
Thermofisher).
Where indicated, HUVEC monolayers or CLL 
suspensions were preincubated for 30 min with Fc 
fragments of human IgG (hFc; 1 μg/mL; Jackson) 
in the presence or not of saturating amounts of hFc 
tagged recombinant extracellular domain dimers of 
human ephrinA4 (ephrinA4Fc; R&D) (0.5 μg/mL; 30 
min), EphA2 (EphA2Fc, 0.5 μg/106 cells), VCAM-1 
(rhVCAM-1) (0.2 μg/106 cells) or ICAM-1 (rhICAM-1) 
(all from R&D). Saturating concentrations were 
determined by flow cytometry using an anti hFc or poly-
His antibody as previously described [16].
Suspension cultures onto plate immobilized 
integrin ligands
Recombinant cell adhesion molecules ICAM-
1 and VCAM-1 (5 μg/mL each)( R&D), extracellular 
matrix proteins (EMP) including fibronectin (FN, 10 μg/
mL), vitronectin (VN, 10 μg/mL), laminin (LM, 10 μg/
mL), type I collagen (10 μg/mL) (all from BD) or control 
protein (BSA; 5 μg/mL; Sigma) were bound to the flat-
surface of 96-well culture plates (96 × multiwell culture 
plates, Corning) for 2 hours at 37°C. Where indicated 
CLL cell suspensions were incubated for 30 min with 
recombinant EphA2Fc (0.5 μg/106 cells) and purified 
hFc fragments of human Igs (1 μg/106 cells, Jackson) and 
extensively washed in culture medium before addition 
to culture wells (5×105/well). All cultures were done 
in 200 μl final volume of freshly prepared RPMI-1640 
supplemented with pyruvate (1mM), L-Gln (1 mM) and 1 
% FCS in a humidified incubator (5% CO2, 37°C).
Coculture assays
Confluent monolayers of HUVEC were grown in 
multiwell plates (96x wells plastic culture plates, Corning). 
HUVEC activation was performed by providing 10ng/ml 
TNFα (PeProtech, Europe) to the culture medium for 4 hours 
followed by extensive washing in fresh medium without 
cytokine. TNFα activated or untreated HUVEC monolayers 
were used alive or fixed in 4% paraformaldehyde (PF) 
in PBS for 20 min followed by extensive washing in 
fresh medium. CLL cell suspensions (5×105 / well) were 
harvested from cocultures or control suspension cultures 
without HUVEC at the indicated time points by extensive 
washing in PBS containing 5 mM EDTA.
siRNA knock-down assays
Mixed siRNAs duplexes targeting different exons 
of ephrinA4 (Supplementary Material and Methods) or 
negative control duplexes (Stealth RNAi negative control 
duplexes, medium-GC, Invitrogen) were nucleofected 
(300 nM) following manufacturer’s recommendations 
(Amaxa, nucleofection reagents #4DV4XP-3024; 
4D-Nucleofector X-unit). EphrinA4 protein knock-down 
Oncotarget48497www.impactjournals.com/oncotarget
and CLL viability were analyzed by flow cytometry 48 
hours postnucleofection.
Flow cytometry analysis
Cell suspensions were incubated with PE 
conjugated Annexin-V in HEPES buffer (ImmunoStep, 
Spain) followed by incubation with 7-AAD solution 
(5 μg/mL) until analysis in a four-color flow cytometer 
(FACScalibur, BD; Flow Cytometry and Fluorescence 
Microscopy Centre, UCM). Absolute cell counts were 
measured by flow cytometry. Briefly, total recovered cells 
were suspended in equivalent final volumes of PBS to 
which equivalent concentrations of fluorescent counting 
beads were added (CountBrigth absolute counting beads, 
ThermoFisher). Acquisition was performed at low speed 
for 1 min. Absolute cell counts were determined according 
to the following formula:
(Number of B-cell events / Number of bead events) 
× number of beads added
For immunofluorescent staining cell suspensions 
were incubated in cold PBS [0.1% bovine serum albumin 
(BSA)] (2×105 cells/50 μL) with saturating amounts of 
antibodies to human antigens including: anti-CD19 (FITC, 
APC or PE), -CD5 (PECy5); FITC or PE-Cy5 anti-CD11a 
(αL;), -CD29 (β1), -CD18 (β2) or -CD49d (α4)(all from 
ImmunoStep, Spain); PE conjugated anti ZAP-70 or 
APC-CD38 (BD). Biotinilated goat-anti human ephrinA4 
polyclonal Ab (R&D, Vitro, Spain) in the presence of 
purified goat IgG immunoglobulins (Jackson Immuno-
Research, Europe) followed by streptavidin (SAV)-
AlexaFluor-488 (Invitrogen).
Quantification of soluble ephrinA4 in serum by 
ELISA
Indirect ELISAs were carried out as previously 
described [18]. Briefly, plates (MaxiSorp Nunc-
Immunoplates, Nunc) were preincubated with an anti-
human ephrinA4 goat polyclonal antiserum (R&D) for 
antigen capture followed by addition of 100 μL serum 
samples diluted two to eightfold in binding buffer (TBS, 
0.5% Tween 20). After 4h incubation, the bound ephrinA4 
was detected by incubating wells with a biotinylated anti-
ephrinA4 antibody followed by SAV-HRPO conjugate 
(Jackson-Immunoresearch). Absorbance readings were at 
405 nm (reference wavelength 492 nm) on a microplate 
reader (Bio-Tek Instruments). Standard curves were 
generated with serial dilutions of a recombinant human 
ephrinA4 (R&D) (ng/ml).
Integrin activation state and ligand binding 
assays
CLL cell suspensions (106 /mL) were preincubated 
for 30 min (37°C) in RPMI/2%FCS culture medium, 
with or without MnCl2 (1mM), containing purified Fc 
fragments of human IgG (Jackson). Next, cells were 
maintained in the same binding medium and incubated 30 
min with recombinant human EphA2 (0.5 μg/106 cells). To 
detect activated VLA4, cells were incubated in cold PBS 
with PE-conjugated HUTS-21 mAb (Becton Dickinson). 
To analyze soluble ligand binding, VCAM-1-Fc were 
preclustered with a PE-conjugated affinity pure F(ab’)2 
fragment goat anti-human IgG, Fc gamma fragment 
specific (Jackson Immunoresearch) before addition to the 
EphA2Fcc-preincubated CLL cell suspensions.
Fluorescence microscopy studies
Fluorescence microscopy studies were performed, 
accordingly, onto 1) paraformaldehyde fixed (4% in 
PBS, 30 min) transwell filters from TEM assays, 2) 
acetone fixed (10 min) tissue cryo-sections from CLL 
lymphadenopathies (7 μm thick; Leica cryo-cutter,−22°C), 
3) CLL cell suspensions adhered onto microscope slides 
and fixed in paraformaldehyde solution (4% in PBS, 
30 min) or 4) CLL-HUVEC co-cultures in 16xwell 
glass chamber slides (Corning) as previously described 
[16]. FITC coupled TUNEL detection kit was used 
according to manufacturer recommendations (Roche). 
Immunofluorescence stainings were done in humidified 
chambers in 100 μl PBS (0.1%BSA) containing 0.1 μg/
mL antibodies (Supplementary Material and Methods). 
Nuclei were counterstained with Hoechst (5 μg/mL, 10 
min; Thermofisher). Samples were mounted with a non-
fluorescent anti-fading mounting solution (ProlongGold, 
Thermofisher). Confocal images were acquired in a laser 
confocal microscope system (Leica, TCS SP2 AOBS; 
Flow Cytometry and Fluorescence Microscopy Centre, 
UCM).
Image analyses tools and procedures were 
performed with Image J (Supplementary Material and 
Methods).
Xenograft assays in mice
Germ-free BALB/c mice (Charles River 
Laboratories) were intravenously injected through the 
tail vein with CFSE prestained (10 μM, Thermofisher) 
human CLL cells (20×106 cells per mice) in 20 μl sterile 
PBS solution with or without different concentrations 
of ephrinA4 purified from serum of CLL patients 
(Supplementary Material and Methods). Animals were 
sacrificed by anesthesia 48 hours later and cell suspensions 
from surgically removed popliteal lymph nodes were 
stained with an APC conjugated anti mouse CD45 Ab 
(BD), Annexin-PE and 7AAD for flow cytometry analysis 
(107 total cells per staining). Human CLL cells were gated 
according to positivity for CFSE within the mouse CD45 
negative cell population (Supplementary Figure S1). The 
minimum number of animals per experimental condition 
and CLL sample was prospectively calculated (SPSS 
Sample Power 3; power, 0.8; α < 0.05). Animal studies 
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were approved by the Ethical and Research Committee in 
Animal Experimentation of the Complutense University 
of Madrid.
Statistical analysis
All in vitro assays were done in triplicate wells and 
results are shown as mean (±SD). Statistical analyses were 
performed in SPSS IBM or StatGraphics Centurion XVI. 
Spearman correlation coefficient was used to measure 
interrelatedness of variables and significance determined by 
using the Kruskal Wallis test. Normal distribution of data 
was determined by Shapiro-Wilks test. Normally distributed 
data were compared by paired or unpaired, accordingly, 
two-tailed Student’s t-test [*, P< 0.05; **, P<0.01; ***, 
P<0.001; ns, not statistically significant (P≥0.05)].
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